INTRODUCTION: The @entity753 ( @entity753 ) are a group of undertreated genetically inherited @entity4977 that lead to severely elevated @entity165 levels and early onset @entity65 . @entity146 and lipid-lowering medications such as statins and @entity6741 sequestrants are the backbone of current treatment. Despite these interventions, homozygous @entity753 (HoFH) @entity1 are unable to reach @entity11429 targets and remain at significantly increased risk of @entity65 . Recently, two novel lipid-lowering medications, @entity9033 and mipomersen, have been approved for the treatment of HoFH. CASE DESCRIPTIONS: We present two @entity1 with HoFH who have been unable to reach target @entity11429 goals on standard therapy. @entity1 A is a 41-year-old male and @entity1 B is a 64-year-old female, both of whom have complex histories of @entity453 . In attempt to improve their @entity11429 levels and lower their cardiovascular risk, @entity9033 and mipomersen were initiated in @entity1 A and B, respectively. DISCUSSION/CONCLUSION: Through inhibition of the microsomal @entity412 transfer protein, @entity9033 prevents the formation of @entity412 rich lipoproteins. Mipomersen is an antisense oligonucleotide that inhibits the translation of @entity755 . Both medications employ novel mechanisms developed through advances in pharmacogenetic technology and achieve unprecedented @entity11429 reductions.

Pharmacogenetics in the Development of Lipid Lowering Medications: XXXX _ Mipomersen in Clinical Practice.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient'] @entity753 :: ('OMIM:143890', 'Disease') :: ['FH', 'familial hypercholesterolemias'] @entity146 :: ('MESH:D001523', 'Disease') :: ['Aggressive lifestyle modifications'] @entity9033 :: ('MESH:C473731', 'Chemical') :: ['lomitapide'] @entity755 :: ('338', 'Gene') :: ['apolipoprotein B-100'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity6741 :: ('CHEBI:3098', 'Chemical') :: ['bile acid'] @entity4977 :: ('MESH:D052439', 'Disease') :: ['disorders of lipid metabolism'] @entity11429 :: ('22796', 'Gene') :: ['LDL-C'] @entity453 :: ('MESH:D003324', 'Disease') :: ['multi-vessel coronary artery disease'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity9033 :: (MESH:C473731,Chemical) :: ['Lomitapide']
